GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Down 13.2% in May

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a significant decrease in short interest in May. As of May 15th, there was short interest totalling 776,700 shares, a decrease of 13.2% from the April 30th total of 895,100 shares. Approximately 8.7% of the shares of the stock are sold short. Based on an average daily volume of 510,100 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Investors Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently made changes to their positions in GOVX. Northern Trust Corp purchased a new position in GeoVax Labs in the 4th quarter worth about $29,000. Jane Street Group LLC purchased a new position in GeoVax Labs in the 1st quarter worth about $27,000. Geode Capital Management LLC increased its stake in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after buying an additional 33,440 shares during the period. Citadel Advisors LLC purchased a new position in GeoVax Labs in the 4th quarter worth about $104,000. Finally, Armistice Capital LLC purchased a new position in GeoVax Labs in the 1st quarter worth about $703,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on GOVX shares. D. Boral Capital decreased their price target on shares of GeoVax Labs from $14.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Alliance Global Partners decreased their price target on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday, April 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Wednesday, April 16th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $11.10.

GeoVax Labs Trading Up 6.7%

Shares of GOVX opened at $1.12 on Thursday. GeoVax Labs has a twelve month low of $0.73 and a twelve month high of $11.18. The company has a market cap of $17.02 million, a P/E ratio of -0.31 and a beta of 3.47. The company’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.67.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.14. The firm had revenue of $1.64 million during the quarter, compared to analysts’ expectations of $0.75 million. Analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.